Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-10 (IL-10) receptor complex is a cell-surface heterotetrameric receptor composed of two ligand-binding alpha subunits (IL-10RA) and two accessory beta subunits (IL-10RB). Primarily expressed on hematopoietic cells, this type II cytokine receptor complex plays a critical role in maintaining immune homeostasis and limiting inflammatory tissue damage. Upon binding of the homodimeric IL-10 cytokine, the receptor complex undergoes a conformational change that activates constitutively associated Janus kinases (JAK1 and TYK2), leading to the phosphorylation and nuclear translocation of STAT3. This signaling cascade suppresses the transcription of pro-inflammatory cytokines (such as TNF-alpha, IL-1, and IL-6) in myeloid cells, while paradoxically promoting the survival, proliferation, and cytotoxic activity of CD8+ T cells and natural killer (NK) cells in specific contexts.
In clinical pathology, genetic deficiencies or mutations in IL-10RA or IL-10RB lead to severe, early-onset inflammatory bowel disease (VEO-IBD) due to uninhibited intestinal inflammation. Conversely, overexpression of the IL-10 pathway in the tumor microenvironment can facilitate tumor immune evasion by suppressing dendritic cell maturation and antigen presentation. Therapeutic strategies targeting this receptor complex are dual-natured: long-acting agonists, such as pegilodecakin, and gene therapies, like XT-150, are developed to either stimulate anti-tumor immunity in oncology or restore immune tolerance in chronic inflammatory conditions. Meanwhile, receptor-blocking monoclonal antibodies are being investigated to alleviate immunosuppression in cancer and chronic infections, though managing the risk of autoimmune-like toxicities and hematological side effects remains a key therapeutic challenge.
Agonism of the receptor complex activates the JAK1/TYK2-STAT3 pathway to suppress pro-inflammatory cytokines or stimulate cytotoxic T-cell activity, while antagonism blocks immunosuppressive signaling to enhance anti-tumor immunity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-10 receptor complex (IL-10R).